CimCure

Description

CimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy tumour-supporting blood vessels for treatment of solid tumours.

CimCure is located in the Netherlands ecosystem.

Related

• TTolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• CCeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…
• CyclomicsCyclomics develops molecular diagnostics and DNA sequencing products including the CySeq consensus sequencing and liquid biopsy platform…
• Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
• OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…